RESUMO
Objective To evaluate the effectiveness of melformin sustained release tablets in treatment of patients with abnormal glucose tolerance. Methods 78 cases with abnormal glucose tolerances were selected and divided into two groups. Patients in treatment group took melformin sustained release tablets, while patients in control group took normal therapy. The impaired glucose tolerance (IGT) and body mass index (BMI) were observed and compared. Results The blood glucose level of OGTT 2 h in treatment group was (7.61±1.04)mmol/L, while it was only (9.96±1.08) mmol/L in control group. The BMI of treatment group was 23.71±3.41, while it was 29.53±3.72 in control group. The glycosylated hemoglobin was (5.79±0.41)%, while it was (6.23±0.52)%in control group. The fasting blood glucose in treatment group was (5.34±0.39)mmol/L and in control group was (8.16±0.48)mmol/L. The differences of those indicators between two groups were signiifcant. Conclusion Melformin gains excellent clinical effects in treating patients with abnormal glucose tolerance. It can adjust blood glucose, improve glucose tolerance, and decrease blood glucose level of OGTT 2 h and BMI effectively.